PFENEX

PFNX AMEX
6.21
+0.27
+4.55%
Opening 12:21 07/23 EDT
Open
5.93
Prev Close
5.94
High
6.30
Low
5.79
Volume
119.47K
Avg Vol (3M)
165.83K
52 Week High
7.64
52 Week Low
3.130
% Turnover
0.38%
Market Cap
195.63M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers PFENEX PFNX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
MORE >

Recently

Name
Price
%Change